Lindsey Jardine

Lindsey Jardine is a senior-level clinical and regulatory consultant specializing in novel Class III neurotechnology. She has guided multiple Breakthrough Designation devices through FDA pathways, from early feasibility to pivotal trials, with a current focus on first-in-human studies and closed-loop stimulation systems. With a background spanning startups and cross-functional teams, Lindsey is known for aligning regulatory, clinical, and business goals into cohesive strategies that accelerate development without compromising rigor. Her work centers on helping teams navigate ambiguity. Whether it’s shaping trial design, building evidence frameworks, or translating innovative tech into meaningful patient outcomes. She’s looking forward to this panel discussion on regulated neurotech, and to sharing practical insights from the field where strategy meets execution.